Cocrystal Pharma (COCP) Cost of Revenue (2010 - 2013)

Cocrystal Pharma (COCP) has 4 years of Cost of Revenue data on file, last reported at $1.4 million in Q2 2013.

• For the quarter ending Q2 2013, Cost of Revenue fell 51.27% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2013 stood at $7.9 million (down 31.63% YoY), and the FY2012 full-year result was $10.0 million, changed 0.5% from the prior year.
• Cost of Revenue fell to $1.4 million in Q2 2013, from $1.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $4.7 million in Q4 2011 to a low of $138088.0 in Q1 2011.
• A 4-year average of $2.2 million and a median of $2.1 million in 2012 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 1395.34% in 2012, while the deepest fall reached 54.32% in 2012.
• Tracing COCP's Cost of Revenue over 4 years: stood at $2.9 million in 2010, then soared by 63.96% to $4.7 million in 2011, then plunged by 54.32% to $2.2 million in 2012, then slumped by 34.73% to $1.4 million in 2013.
• Business Quant data shows COCP's Cost of Revenue at $1.4 million in Q2 2013, $1.4 million in Q1 2013, and $2.2 million in Q4 2012.